Company profile
Novaremed Ltd. (subsidiary of Novaremed AG)
Privately held: no public share price (Privately-held clinical-stage biopharma. Novaremed Ltd. (Israel, founded 2008) is the operating subsidiary of parent Novaremed AG (Switzerland, founded 2017), developing nispomeben (NRD135S.E1) for painful diabetic peripheral neuropathy. No evidence of a public listing or SPAC transaction found. Sources: https://clinicaltrials.gov/study/NCT02345291 ; https://www.novaremed.com/ ; https://www.businesswire.com/news/home/20201218005198/en/Novaremed-Receives-Fast-Track-Designation-from-the-FDA-for-NRD135S.E1-for-the-Treatment-of-Painful-Diabetic-Peripheral-Neuropathy Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | —Small molecule | Diabetic Peripheral Neuropathic Pain |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.